SCHEMBL29344185

SCHEMBL29344185

Cc1cc(O)c2ccccc2c1Br

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.63
LMNA P02545 1/20 0.63
KDM4E B2RXH2 3/20 0.49
MAPT P10636 3/20 0.49
HSD17B10 Q99714 2/20 0.49
GAA P10253 2/20 0.49
TP53 P04637 1/20 0.49
TRPM4 Q8TD43 1/20 0.45
IDO1 P14902 2/20 0.44
POLB P06746 2/20 0.42
MEN1 O00255 1/20 0.41
NSD2 O96028 1/20 0.41
KMT2A Q03164 1/20 0.41
MCL1 Q07820 1/20 0.41
EP300 Q09472 1/20 0.40
PKM P14618 2/20 0.39
CYP1A2 P05177 2/20 0.39
ALDH1A1 P00352 2/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24652316 0.83 HTT (0.52) HTTLMNAKDM4EMAPTHSD17B10
SCHEMBL20669532 0.79 CYP1A2 (0.50) HTTLMNAKDM4EHSD17B10GAA
SCHEMBL19544389 0.77 TRPM4 (0.46) HTTLMNAKDM4EMAPTHSD17B10
Vitamin K3H2 SCHEMBL297164 0.77 HTT (1.00) HTTLMNAKDM4EMAPTHSD17B10
SCHEMBL4631028 0.77 HTT (0.68) HTTLMNAKDM4EMAPTHSD17B10
Vitamin K3H2 SCHEMBL29525544 0.77 HTT (1.00) HTTLMNAKDM4EMAPTHSD17B10
SCHEMBL7531782 0.77 ALDH1A1 (0.44) HTTLMNAMAPTMEN1KMT2A
Vitamin K3H2 SCHEMBL2887680 0.76 HTT (0.95) HTTLMNAKDM4EMAPTHSD17B10
SCHEMBL13933689 0.74 HTT (0.63) HTTLMNAKDM4EMAPTHSD17B10
SCHEMBL25240083 0.74 CYP1A2 (0.44) HTTLMNAKDM4EMAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239788-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT TAIHO PHARMACEUTICAL CO., LTD. (JP) 2024-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239788-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT KRAS, NRAS, HRAS HTT 2710/4885LMNA 4027/4885KDM4E 3110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.